ANIP Q4 2024 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q4 2024 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$191M+44.8% YoY

Gross Profit

$110M57.9% margin

Operating Income

-$4M-2.3% margin

Net Income

-$10M-5.4% margin

EPS (Diluted)

$-0.55

QoQ Revenue Growth

+28.5%

Cash Flow

Operating Cash Flow

$16M

Free Cash Flow

$13M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$1.3B

Total Liabilities

$855M

Stockholders' Equity

$429M

Cash & Equivalents

$145M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$191M	$132M	+44.8%
Gross Profit	$110M	$78M	+41.0%
Operating Income	-$4M	$7M	-165.1%
Net Income	-$10M	$1M	-989.7%

Geographic Segments

UNITED STATES

$182M96%

Non-US

$8M4%